The podcast episodes discuss the use of CRISPR technology in potential gene-editing treatments for severe sickle cell disease and beta thalassemia.

The episodes explore how CRISPR works, its potential benefits, and the regulatory and access challenges surrounding these novel therapies.

For example, episode Sickle cell gene-editing treatment poised for FDA approval delves into the specifics of a CRISPR-based treatment for sickle cell disease, while episode U.K. approves world's first gene-editing therapy discusses the approval of a CRISPR therapy for sickle cell and beta thalassemia in the UK, and its potential approval in the US.